v3.26.1
Significant information for the first half of 2026 - Additional information (Details)
$ / shares in Units, € in Millions, $ in Billions
 5 Months Ended 6 Months Ended
Mar. 06, 2026
Feb. 10, 2026
EUR (€)
Jun. 30, 2026
EUR (€)
Jun. 30, 2026
EUR (€)
Jun. 30, 2025
EUR (€)
Feb. 10, 2026
USD ($)
$ / shares
Disclosure of detailed information about business combination [line items]            
Net cash flow on acquisition [1]       € 1,408 € 538  
Medley            
Disclosure of detailed information about business combination [line items]            
Percentage of ownership interest disposed 100.00%          
Dynavax            
Disclosure of detailed information about business combination [line items]            
Equity interests of acquirer (in USD per share) | $ / shares           $ 15.50
Equity value of acquirer | $           $ 2.2
Short-term debt   € 249       $ 0.3
Goodwill   204        
Net cash flow on acquisition   € 1,403        
Dynavax | Biopharma            
Disclosure of detailed information about business combination [line items]            
Revenue of acquiree since acquisition date     € 144      
Operating income of acquiree since acquisition date     89      
Loss of acquiree since acquisition date     63      
Amortization of intangible assets of acquiree since acquisition date     38      
Amortisation of Inventories     44      
Restructuring and similar costs     € 63      
[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2026, this line item includes the net cash outflow arising from the acquisition of Dynavax (see Note B.1.1.). For the six months ended June 30, 2025 it includes the net cash outflow arising from the acquisition of Dren-0201.